Top Markets
#1 BOOK OF MEME BOOK OF MEME +26.80%
#2 XPIN Network XPIN Network +23.44%
#3 SSV Network SSV Network +22.92%
#4 The Black Bull The Black Bull +19.80%
#5 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +17.07%
#6 Bitcoin Cash Bitcoin Cash +16.56%
#7 Mubarak Mubarak +16.49%
#8 Geodnet Geodnet +16.21%
#9 Neiro Neiro +15.03%
#10 Derive Derive +13.77%
Coin of the day
BOOK OF MEME BOOK OF MEME
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
ATyr Pharma, Inc. ATyr Pharma, Inc.

ATyr Pharma, Inc.

ATYR
Kedudukan dalam Saham #25453
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego,... aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Harga Saham
$0.5049
Disegerakkan terakhir: 2026-08-20
Modal Pasaran
$49.51M
Perubahan (1 hari)
-5.24%
Perubahan (1 tahun)
-89.80%
Negara
US
Perdagangan ATyr Pharma, Inc. (ATYR)

Kategori

Healthcare
Nisbah P/E bagi ATyr Pharma, Inc. (ATYR)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini ATyr Pharma, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi ATyr Pharma, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.